Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) – Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Antisense Therapeutics Limited

Atox Bio Ltd.

Biogen Inc

BioMAS Ltd.

Daiichi Sankyo Company, Limited

EA Pharma Co Ltd

Protagonist Therapeutics Inc.

Takeda Pharmaceutical Company Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Overview 7

Therapeutics Development 8

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Stage of Development 8

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Therapy Area 9

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Indication 10

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Companies 14

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development 24

Antisense Therapeutics Limited 24

Atox Bio Ltd. 25

Biogen Inc 26

BioMAS Ltd. 27

Daiichi Sankyo Company, Limited 28

EA Pharma Co Ltd 29

Protagonist Therapeutics Inc. 30

Takeda Pharmaceutical Company Limited 31

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles 32

AB-103 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ATL-1102 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

carotegrast - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

CB-0602 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

natalizumab - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

PTG-100 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

vedolizumab - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Projects 60

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products 65

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Featured News & Press Releases 66

Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn’s Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting 66

Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 67

Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys 68

Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna 70

Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients 70

Sep 28, 2016: Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 71

Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 72

Sep 08, 2016: Biogen Presents Data on TYSABRI at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis 74

Jun 17, 2016: Antisense Therapeutics provides update on ATL1102 for Multiple Sclerosis 75

Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections 76

Jun 01, 2016: Antisense provides update on ATL1102 clinical trials 76

May 31, 2016: Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy 77

May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authorisation for Tysabri (natalizumab) 78

May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting 78

May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Antisense Therapeutics Limited, H2 2016 24

Pipeline by Atox Bio Ltd., H2 2016 25

Pipeline by Biogen Inc, H2 2016 26

Pipeline by BioMAS Ltd., H2 2016 27

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 28

Pipeline by EA Pharma Co Ltd, H2 2016 29

Pipeline by Protagonist Therapeutics Inc., H2 2016 30

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 31

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

Dormant Projects (Contd..2), H2 2016 62

Dormant Projects (Contd..3), H2 2016 63

Dormant Projects (Contd..4), H2 2016 64

Discontinued Products, H2 2016 65

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports